Drug class review on disease-modifying drugs for multiple sclerosis final report
Multiple Sclerosis (MS) is a chronic, autoimmune disease of the central nervous system (CNS) that affects about 250,000 people in the United States, although estimates are as high as 400,000 people. The treatment of MS involves acute relapse treatment with corticosteroids, symptom management with ap...
| Main Author: | |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Portland, Or.
Oregon Health & Science University, Evidence-Based Practice Center
c2007, 2007
|
| Series: | Drug class reviews
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Multiple Sclerosis (MS) is a chronic, autoimmune disease of the central nervous system (CNS) that affects about 250,000 people in the United States, although estimates are as high as 400,000 people. The treatment of MS involves acute relapse treatment with corticosteroids, symptom management with appropriate agents and disease modification with disease-modifying drugs (DMD). These agents modify the immune response that occurs in MS through various immunomodulatory or immunosuppressive effects. The purpose of this review is to compare the effectiveness and safety of different disease-modifying drugs for the treatment of MS. |
|---|---|
| Item Description: | "July 2007." |
| Physical Description: | PDF file (70 p.) |